Teva's Cinqair OK'd, But Narrower Use Than GSK's Nucala
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries Ltd. gained US approval on March 23 to market Cinqair (reslizumab) as an add-on maintenance treatment for adults 18 years or older with severe asthma with an eosinophilic phenotype.